Developer docs
API playgroundTry for free, no card

Search company profiles

Dimension Inx

Full company profile

uuid0000aug

Namestring
Dimension Inx
Legal namestring
Dimension Inx Corp.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Dimension Bio (formerly Dimension Inx) is a Chicago-based, venture-backed regenerative therapeutics company founded in 2017 that designs, develops, and manufactures 3D-printed biomaterial scaffolds intended to direct tissue regeneration and healing. Its foundational technology is the BioNidum platform, a bioinspired system that fuses materials science, 3D printing, and digital manufacturing to engineer regenerative microenvironments with independent control of material composition, three-dimensional architecture, and microstructure. The platform underpins multiple proprietary material families, including the Hyperelastic Bone composite (hydroxyapatite particles in a biodegradable PLG polymer), the Fluffy-X highly tunable porous material family, and the Tissue Papers decellularized ECM-based material family, supported by issued U.S. patents and proprietary manufacturing know-how rooted in nearly a decade of research at Northwestern University's Tissue Engineering and Additive Manufacturing Lab.

The company's commercial lead asset is CMFlex, the first FDA 510(k)-cleared 3D-printed regenerative bone graft (cleared December 2022), positioned as a ready-to-use flexible ceramic for oral and maxillofacial bone reconstruction. Revenue mechanics span three streams: (1) product sales of CMFlex to healthcare institutions via direct enterprise sales engagement with oral/maxillofacial, plastic/reconstructive, dental, and orthopedic surgeons, with an initial limited release to key opinion leader surgeons followed by broader commercial rollout; (2) biotech partner collaborations structured as professional services or co-development arrangements for biomaterial and regenerative product challenges; and (3) internal therapeutic product development targeting high-unmet-need indications including liver failure and Type 1 diabetes via BioNidum-based cell delivery scaffolds, with future licensing and royalty potential. Through November 2025 the company has raised approximately $17.8M in cumulative funding across seed, government, and Series A rounds, with a 11-50 employee headcount and an explicit strategic emphasis on scaling manufacturing and clinical development beyond the initial bone graft indication.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative therapeutics, 3D-printed bone grafts, biomaterials platform, tissue engineering, medical device manufacturing
Industry4 codes
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAEAD
Medical Devices & Dental (Production AM Parts)
Industrials, Manufacturing & Construction/3D Printing/Additive Manufacturing for Production Parts (Industrial End-Use)
NAICS code1 code
  • Dental Laboratories339116
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Regenerative Medicine / Tissue Engineering Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales - CMFlex
TypeOne Time License
Description

Sale of FDA-cleared 3D-printed regenerative bone graft product CMFlex for oral and maxillofacial surgical applications. Initially targeting key surgeons with broader commercial release planned.

dimension.bio
2Biotech Partner Collaborations
TypeProfessional Services
Description

Working shoulder-to-shoulder with biotech partners to solve challenging materials problems, including co-development of regenerative products for therapeutic applications.

dimension.bio
3Internal Therapeutic Product Development
TypeLicensing Royalties
Description

Internally developing regenerative products for therapeutic applications with high unmet clinical need including organ restoration, cell therapies for liver failure and type 1 diabetes.

dimension.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1CMFlex
Description

First 3D-printed regenerative bone graft product cleared by the FDA, a ready-to-use flexible ceramic graft for oral and maxillofacial indications.

dimension.bio
+4 more records
Core offering1 text field

Dimension Inx designs, develops, and manufactures regenerative biomaterial products on its proprietary BioNidum platform, which fuses materials science, 3D printing, and digital manufacturing to engineer microenvironments that drive tissue healing. Its commercial lead product is CMFlex, the first FDA-cleared 3D-printed regenerative bone graft for oral and maxillofacial applications. The company also licenses its platform for internal therapeutic product development (cell therapies for liver failure and Type 1 diabetes) and co-develops regenerative products with biotech partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First 3D-printed regenerative bone graft product cleared by FDA
+1 more record
Product overview1 text field

Dimension Bio (formerly Dimension Inx) operates a platform-based business model centered on its BioNidum™ platform, which serves as the foundation for developing implantable and injectable biosynthetic products for regenerative therapeutics. The company develops products both internally and in partnership with biotech companies. The commercial product portfolio includes CMFlex™ (FDA-cleared 3D-printed regenerative bone graft), while material technology families include Fluffy-X™ (porous tunable materials) and Tissue Papers™ (decellularized ECM materials), all built on the proprietary Hyperelastic Bone® composite technology.

Product and service5 records
1CMFlex
Category3D-printed regenerative bone graft (medical device)
Description

CMFlex is the first FDA-cleared 3D-printed regenerative bone graft, a ready-to-use flexible ceramic graft for oral and maxillofacial bone reconstruction. It uses Dimension Bio's proprietary Hyperelastic Bone composite material of hydroxyapatite particles and PLG polymer, with fluid absorption capability for hemostasis, bone remodeling, and tissue integration.

2BioNidum Platform
CategoryBiomaterials and 3D-printing platform technology
Description

BioNidum is Dimension Bio's bioinspired platform that fuses materials science, 3D printing, and digital manufacturing to engineer regenerative microenvironments that influence cell behavior, tissue organization, and healing. It provides independent control of material composition, 3D architecture, and microstructure, supporting development of implantable and injectable biosynthetic products tailored to different tissues and clinical applications.

3Fluffy-X Material Family
CategoryPatented biomaterial family
Description

Fluffy-X is a highly tunable and porous biomaterial family covered by U.S. Patent No. 11,896,740, developed from nearly a decade of research at Northwestern University. It offers excellent handling properties and mechanical integrity for regenerative applications.

4Tissue Papers Material Family
CategoryPatented biomaterial family
Description

Tissue Papers is a decellularized ECM-based biomaterial family covered by U.S. Patent No. 11,904,071, providing control of both material structure and composition for advanced tissue repair constructs and cell delivery applications.

5Hyperelastic Bone (composite material technology)
CategoryProprietary biomaterial composite technology
Description

Hyperelastic Bone is a proprietary microstructurally porous composite material comprised of hydroxyapatite particles combined with biodegradable polylactide-co-glycolide (PLG) polymer. It is 3D-printable and forms the base of the CMFlex bone graft product.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founders Ramille Shah and Adam Jakus developed core technologies from nearly a decade of research at Northwestern University's Tissue Engineering and Additive Manufacturing Lab. Ongoing research relationship.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Integra LifeSciences is a large medical device company with a substantial regenerative technologies portfolio (e.g., Integra Dermal Regeneration Template, bone graft substitutes). Comparable to Dimension Bio as a broad incumbent in regenerative medicine with overlapping product categories in wound/skin regeneration and bone repair, though it serves a much wider portfolio of indications.

TypeDirect peer
Description

Xtant Medical is a pure-play orthobiologics company focused on bone graft substitutes and sports medicine applications. Directly comparable to Dimension Bio's CMFlex in the bone graft substitute market, with overlapping surgeon customers (spine, orthopedic) and a similar product-led commercial model.

TypeDirect peer
Description

LifeNet Health is a leading allograft and regenerative medicine nonprofit, providing bone, soft tissue, and cellular allograft products for surgical use. Comparable to Dimension Bio as a regenerative medicine company serving oral/maxillofacial, orthopedic, and spine surgeons with bone and tissue graft products, although LifeNet primarily uses allograft (donor tissue) versus Dimension Bio's synthetic 3D-printed approach.

TypeDirect peer
Description

MTF Biologics is a nonprofit tissue bank supplying allograft bone grafts, sports medicine grafts, and wound care allografts. Directly comparable to Dimension Bio in the bone graft substitute and regenerative medicine market, serving overlapping surgical specialties with musculoskeletal focus.

TypeDirect peer
Description

NovaBone Products manufactures synthetic bone graft substitutes (calcium phosphosilicate-based) for dental, oral/maxillofacial, and orthopedic applications. Directly comparable to Dimension Bio's CMFlex as a synthetic bone graft competitor targeting oral surgeons and dental implant specialists.

TypeBroad incumbent
Description

Organogenesis is a commercial-stage regenerative medicine company focused on wound care and surgical biologics (Apligraf, Dermagraft, PuraPly). Comparable as a public regenerative medicine company selling FDA-approved biomaterial products to surgeons and hospitals, though it focuses primarily on wound/skin applications rather than bone.

TypeEmerging player
Description

Vericel develops advanced cell therapies and specialty biologics for the sports medicine and severe burn care markets (MACI, Epicel). Comparable to Dimension Bio as a regenerative medicine company with surgical/orthopedic applications and a cell therapy pipeline, though at a more advanced commercial stage.

TypeBroad incumbent
Description

Stryker is a global medical device leader with a substantial orthobiologics portfolio including bone graft substitutes (Vitoss, OP-1) and regenerative materials for spine, orthopedic, and CMF applications. Comparable as a broad incumbent in the bone graft substitute market Dimension Bio targets with CMFlex, though with much broader product breadth and established sales channels.

TypeDirect peer
Description

MiMedx develops and commercializes regenerative biologics using placental tissue allografts for wound care, surgical recovery, and musculoskeletal applications. Comparable to Dimension Bio as a regenerative medicine company selling biomaterial-based products to surgeons, though it uses placental tissue rather than 3D-printed synthetic constructs.

TypeEmerging player
Description

Organovo is a 3D bioprinting company developing functional human tissues for therapeutic applications and research use. Comparable to Dimension Bio as an emerging player in 3D bioprinting and tissue engineering, though Organovo is focused on liver tissue for research/drug testing rather than surgical implant applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dimension Inx

Regenerative Medicine / Tissue Engineering Medical Devicesdimensioninx.com

What Dimension Inx does

Dimension Bio (formerly Dimension Inx) is a Chicago-based, venture-backed regenerative therapeutics company founded in 2017 that designs, develops, and manufactures 3D-printed biomaterial scaffolds intended to direct tissue regeneration and healing. Its foundational technology is the BioNidum platform, a bioinspired system that fuses materials science, 3D printing, and digital manufacturing to engineer regenerative microenvironments with independent control of material composition, three-dimensional architecture, and microstructure. The platform underpins multiple proprietary material families, including the Hyperelastic Bone composite (hydroxyapatite particles in a biodegradable PLG polymer), the Fluffy-X highly tunable porous material family, and the Tissue Papers decellularized ECM-based material family, supported by issued U.S. patents and proprietary manufacturing know-how rooted in nearly a decade of research at Northwestern University's Tissue Engineering and Additive Manufacturing Lab.

The company's commercial lead asset is CMFlex, the first FDA 510(k)-cleared 3D-printed regenerative bone graft (cleared December 2022), positioned as a ready-to-use flexible ceramic for oral and maxillofacial bone reconstruction. Revenue mechanics span three streams: (1) product sales of CMFlex to healthcare institutions via direct enterprise sales engagement with oral/maxillofacial, plastic/reconstructive, dental, and orthopedic surgeons, with an initial limited release to key opinion leader surgeons followed by broader commercial rollout; (2) biotech partner collaborations structured as professional services or co-development arrangements for biomaterial and regenerative product challenges; and (3) internal therapeutic product development targeting high-unmet-need indications including liver failure and Type 1 diabetes via BioNidum-based cell delivery scaffolds, with future licensing and royalty potential. Through November 2025 the company has raised approximately $17.8M in cumulative funding across seed, government, and Series A rounds, with a 11-50 employee headcount and an explicit strategic emphasis on scaling manufacturing and clinical development beyond the initial bone graft indication.

Dimension Inx firmographics

Firmographics
Name
Dimension Inx
Legal name
Dimension Inx Corp.
Website
https://dimensioninx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Dimension Inx industry classification

Industry
Product category
Regenerative Medicine / Tissue Engineering Medical Devices
NAICS
Dental Laboratories (339116)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAEAD
Medical Devices & Dental (Production AM Parts)
Industrials, Manufacturing & Construction/3D Printing/Additive Manufacturing for Production Parts (Industrial End-Use)

Keywords

  • Regenerative therapeutics
  • 3D-printed bone grafts
  • Biomaterials platform
  • Tissue engineering
  • Medical device manufacturing

Where Dimension Inx is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Dimension Inx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales - CMFlex: Sale of FDA-cleared 3D-printed regenerative bone graft product CMFlex for oral and maxillofacial surgical applications. Initially targeting key surgeons with broader commercial release planned.
  2. Biotech Partner Collaborations: Working shoulder-to-shoulder with biotech partners to solve challenging materials problems, including co-development of regenerative products for therapeutic applications.
  3. Internal Therapeutic Product Development: Internally developing regenerative products for therapeutic applications with high unmet clinical need including organ restoration, cell therapies for liver failure and type 1 diabetes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Dimension Inx product offering

Product offering

Core offering

Dimension Inx designs, develops, and manufactures regenerative biomaterial products on its proprietary BioNidum platform, which fuses materials science, 3D printing, and digital manufacturing to engineer microenvironments that drive tissue healing. Its commercial lead product is CMFlex, the first FDA-cleared 3D-printed regenerative bone graft for oral and maxillofacial applications. The company also licenses its platform for internal therapeutic product development (cell therapies for liver failure and Type 1 diabetes) and co-develops regenerative products with biotech partners.

Product overview

Dimension Bio (formerly Dimension Inx) operates a platform-based business model centered on its BioNidum™ platform, which serves as the foundation for developing implantable and injectable biosynthetic products for regenerative therapeutics. The company develops products both internally and in partnership with biotech companies. The commercial product portfolio includes CMFlex™ (FDA-cleared 3D-printed regenerative bone graft), while material technology families include Fluffy-X™ (porous tunable materials) and Tissue Papers™ (decellularized ECM materials), all built on the proprietary Hyperelastic Bone® composite technology.

Differentiator

Problem solved

Functional benefit

Brands

  • CMFlex: First 3D-printed regenerative bone graft product cleared by the FDA, a ready-to-use flexible ceramic graft for oral and maxillofacial indications.
  • BioNidum
  • Fluffy-X
  • Tissue Papers
  • Hyperelastic Bone

Products and services

  • CMFlex CMFlex is the first FDA-cleared 3D-printed regenerative bone graft, a ready-to-use flexible ceramic graft for oral and maxillofacial bone reconstruction. It uses Dimension Bio's proprietary Hyperelastic Bone composite material of hydroxyapatite particles and PLG polymer, with fluid absorption capability for hemostasis, bone remodeling, and tissue integration.
  • BioNidum Platform BioNidum is Dimension Bio's bioinspired platform that fuses materials science, 3D printing, and digital manufacturing to engineer regenerative microenvironments that influence cell behavior, tissue organization, and healing. It provides independent control of material composition, 3D architecture, and microstructure, supporting development of implantable and injectable biosynthetic products tailored to different tissues and clinical applications.
  • Fluffy-X Material Family Fluffy-X is a highly tunable and porous biomaterial family covered by U.S. Patent No. 11,896,740, developed from nearly a decade of research at Northwestern University. It offers excellent handling properties and mechanical integrity for regenerative applications.
  • Tissue Papers Material Family Tissue Papers is a decellularized ECM-based biomaterial family covered by U.S. Patent No. 11,904,071, providing control of both material structure and composition for advanced tissue repair constructs and cell delivery applications.
  • Hyperelastic Bone (composite material technology) Hyperelastic Bone is a proprietary microstructurally porous composite material comprised of hydroxyapatite particles combined with biodegradable polylactide-co-glycolide (PLG) polymer. It is 3D-printable and forms the base of the CMFlex bone graft product.

Quantifiable outcome

  • First 3D-printed regenerative bone graft product cleared by FDA
  • +1 more outcomes

Companies that use Dimension Inx

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Dimension Inx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Dimension Inx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Northwestern UniversitycoreStrategic or Co-development PartnerCo-founders Ramille Shah and Adam Jakus developed core technologies from nearly a decade of research at Northwestern University's Tissue Engineering and Additive Manufacturing Lab. Ongoing research relationship.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Dimension Inx competitors and assessment

Company assessment

Broad incumbents

  • Integra LifeSciences: Integra LifeSciences is a large medical device company with a substantial regenerative technologies portfolio (e.g., Integra Dermal Regeneration Template, bone graft substitutes). Comparable to Dimension Bio as a broad incumbent in regenerative medicine with overlapping product categories in wound/skin regeneration and bone repair, though it serves a much wider portfolio of indications.
  • Organogenesis: Organogenesis is a commercial-stage regenerative medicine company focused on wound care and surgical biologics (Apligraf, Dermagraft, PuraPly). Comparable as a public regenerative medicine company selling FDA-approved biomaterial products to surgeons and hospitals, though it focuses primarily on wound/skin applications rather than bone.
  • Stryker (Orthobiologics): Stryker is a global medical device leader with a substantial orthobiologics portfolio including bone graft substitutes (Vitoss, OP-1) and regenerative materials for spine, orthopedic, and CMF applications. Comparable as a broad incumbent in the bone graft substitute market Dimension Bio targets with CMFlex, though with much broader product breadth and established sales channels.

Direct peers

  • Xtant Medical: Xtant Medical is a pure-play orthobiologics company focused on bone graft substitutes and sports medicine applications. Directly comparable to Dimension Bio's CMFlex in the bone graft substitute market, with overlapping surgeon customers (spine, orthopedic) and a similar product-led commercial model.
  • LifeNet Health: LifeNet Health is a leading allograft and regenerative medicine nonprofit, providing bone, soft tissue, and cellular allograft products for surgical use. Comparable to Dimension Bio as a regenerative medicine company serving oral/maxillofacial, orthopedic, and spine surgeons with bone and tissue graft products, although LifeNet primarily uses allograft (donor tissue) versus Dimension Bio's synthetic 3D-printed approach.
  • MTF Biologics: MTF Biologics is a nonprofit tissue bank supplying allograft bone grafts, sports medicine grafts, and wound care allografts. Directly comparable to Dimension Bio in the bone graft substitute and regenerative medicine market, serving overlapping surgical specialties with musculoskeletal focus.
  • NovaBone Products: NovaBone Products manufactures synthetic bone graft substitutes (calcium phosphosilicate-based) for dental, oral/maxillofacial, and orthopedic applications. Directly comparable to Dimension Bio's CMFlex as a synthetic bone graft competitor targeting oral surgeons and dental implant specialists.
  • MiMedx: MiMedx develops and commercializes regenerative biologics using placental tissue allografts for wound care, surgical recovery, and musculoskeletal applications. Comparable to Dimension Bio as a regenerative medicine company selling biomaterial-based products to surgeons, though it uses placental tissue rather than 3D-printed synthetic constructs.

Emerging players

  • Vericel: Vericel develops advanced cell therapies and specialty biologics for the sports medicine and severe burn care markets (MACI, Epicel). Comparable to Dimension Bio as a regenerative medicine company with surgical/orthopedic applications and a cell therapy pipeline, though at a more advanced commercial stage.
  • Organovo: Organovo is a 3D bioprinting company developing functional human tissues for therapeutic applications and research use. Comparable to Dimension Bio as an emerging player in 3D bioprinting and tissue engineering, though Organovo is focused on liver tissue for research/drug testing rather than surgical implant applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Dimension Inx compliance and trust

Trust signal

Compliance1 record

Dimension Inx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dimension Inx leadership team

Management profile

Number of profiles

Profiles10 records

Dimension Inx funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dimension Inx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dimension Inx

What does Dimension Inx do?

Dimension Inx designs, develops, and manufactures regenerative biomaterial products on its proprietary BioNidum platform, which fuses materials science, 3D printing, and digital manufacturing to engineer microenvironments that drive tissue healing. Its commercial lead product is CMFlex, the first FDA-cleared 3D-printed regenerative bone graft for oral and maxillofacial applications. The company also licenses its platform for internal therapeutic product development (cell therapies for liver failure and Type 1 diabetes) and co-develops regenerative products with biotech partners.

Is Dimension Inx a public or private company?

Dimension Inx is a private company. It is classified as venture growth investor backed and is currently operating.

When was Dimension Inx founded?

Dimension Inx was founded in 2017. It employs 11 to 50 people.

Where is Dimension Inx based?

Dimension Inx is headquartered in Chicago, United States, in the North America region.

How does Dimension Inx make money?

Three revenue lines are on record. Product Sales - CMFlex is the primary driver. The others are biotech Partner Collaborations and internal Therapeutic Product Development.

Who are Dimension Inx's main competitors?

Broad incumbents on record are Integra LifeSciences, Organogenesis and Stryker (Orthobiologics). Direct peers are Xtant Medical, LifeNet Health, MTF Biologics, NovaBone Products and MiMedx. Emerging players are Vericel and Organovo.

Does Dimension Inx have an API?

No public API is recorded for Dimension Inx.

What industry is Dimension Inx in?

Dimension Inx's product category is Regenerative Medicine / Tissue Engineering Medical Devices. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 339116 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsWhy Dimension Inx co-founder Adam Jakus left to launch a biotech consulting firmAdam Jakus, co-founder of Dimension Inx, left the Chicago biotech startup to launch BioThera3 Advising & Consulting, a biotech consulting firm. He served as CTO from 2017 to 2023 and now focuses on helping companies with regulatory pathways, funding, and partnerships. He remains based in Chicago and plans to engage with universities and tech hubs.NasdaqDesktop Health Announces First Patients Treated with FDA-Cleared CMFlex™ – an Off-the-Shelf 3D Printed Synthetic Bone Graft Product Pioneered by Dimension Inx on the 3D-Bioplotter®Dimension Inx has announced that its FDA-cleared, 3D-printed synthetic bone graft product, CMFlex, has been successfully implanted in multiple patients for jaw and dental surgeries. The product was manufactured using Desktop Health's 3D-Bioplotter system, marking a significant step in clinical adoption for bioprinting technologies. This initial usage highlights the transition of 3D-bioprinted biomaterials from research to commercial patient care.PR NewswireDimension Inx Announces First Surgical Cases Utilizing CMFlex™ Synthetic Bone Graft - The First 3D-printed Regenerative Bone Graft Product Cleared by the FDADimension Inx announced that CMFlex, the first FDA-cleared 3D-printed regenerative bone graft, has been successfully used in its initial clinical cases performed by Dr. Derek Steinbacher and Dr. Brian Farrell. The product utilizes a proprietary composite material designed to promote bone regeneration and control bleeding during oral and maxillofacial surgeries. This milestone follows FDA clearance received in December 2022 and precedes a broader market release planned for later in 2024.Averyfairbank3D Printing: Top 5 Largest Deals 2023In Q1 2023, the 3D Printing Medical Devices sector recorded five major funding deals totaling over £379.5 million, signaling strong investor confidence in medical 3D printing technology. LimaCorporate led with a £260.50 million debt refinancing, followed by ZEDA (£42.90M Series B), Shoulder Innovations (£34.08M Series D), ReLive Biotechnologies (£29.75M Series A plus acquisition of Co.Don AG), and Dimension Inx (£12.37M Series A). The deals span companies in the US, Italy, China, and Germany focused on orthopaedic implants, cartilage regeneration, and regenerative medicine, with two firms also securing FDA 510(k) clearances during the period.PR NewswireDimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior AdvisorDimension Inx, a Chicago-based biomaterials platform company, announced the appointments of Paul K. Wotton, Ph.D. as an Independent Director to its board and Chris Ehrlich as Senior Advisor, both bringing extensive biotech industry experience. Dr. Wotton's appointment fills a board seat created after the company's $15M Series A financing in February 2023, and his background includes leadership roles at multiple biotech firms including Obsidian Therapeutics, Sigilon Therapeutics, and Antares Pharma. The company stated these additions will support its therapeutic development milestones and expansion of its regenerative biomaterials platform.FinSMEsDimension Inx Raises $12M in Series A FundingDimension Inx, a biomaterials platform company based in Chicago, IL, raised $12M in Series A funding led by Prime Movers Lab, with several other investors participating. The funds will support the development of therapeutic products aimed at functional organ restoration and the commercial launch of their first product, CMFlex™, which has also received FDA clearance. The company aims to advance its manufacturing capabilities and expand its market presence in the medical device sector.DimensioninxPress Release — Dimension BioDimension Inx, a biomaterials platform company based in Chicago, has raised $12 million in a Series A funding round led by Prime Movers Lab. The funding will support the commercialization of their first product, CMFlex™, which has recently received FDA 510(k) clearance and is designed for oral and maxillofacial applications to restore bone functionality. This milestone marks a significant step in advancing their regenerative therapeutic products.PrwebDimension Inx Raises $12M Series A to Accelerate Commercialization of New Generation of Regenerative TherapeuticsDimension Inx closed a $12 million Series A funding round led by Prime Movers Lab, with participation from KdT Ventures, Revolution's Rise of the Rest Seed Fund, Solas BioVentures, Portal Innovation Ventures, and Alumni Ventures. The company simultaneously received U.S. FDA 510(k) clearance for CMFlex™, marking it as the first 3D-printed regenerative product cleared by the agency.VC News DailyDimension Inx Snares $12M Series ADimension Inx has closed a $12 million Series A funding round led by Prime Movers Lab, with participation from existing investors KdT Ventures and Revolution's Rise of the Rest Seed Fund. New investors in this round include Solas BioVentures, Portal Innovation Ventures, and Alumni Ventures. The company utilizes its 3D-Painting Materials Design and Manufacturing System to develop tissue-engineered regenerative medical products.